Cardiovascular · Topic 33 of 48

Prosthetic Heart Valves

Cardiovascular · valve replacement

Prosthetic Heart Valves

A mechanical valve means lifelong warfarin to an INR of 2.5 or 3.0 — never a DOAC — and a muffled click means thrombosis until proven otherwise.

Key numbers

Target INR 2.5, or 3.0 with riskINR 2.5 / 3.0

01 · GiveMechanical valve: lifelong warfarin, never a DOAC

Every mechanical valve needs lifelong vitamin K antagonist (warfarin); DOACs are ineffective and contraindicated — dabigatran caused more thrombosis and bleeding (RE-ALIGN) and apixaban was inferior for On-X aortic valves (PROACT Xa).

02 · The numberTarget INR 2.5, or 3.0 with risk

Target INR 2.5: bileaflet mechanical aortic valve without risk factors. Target 3.0: mechanical mitral (or tricuspid) valve, older-generation aortic prosthesis, or aortic valve with AF, LVEF < 35%, prior thromboembolism or hypercoagulability.

03 · Watch forMuffled clicks with new dyspnea: valve thrombosis

Obstructive mechanical valve thrombosis (eg, after stopping warfarin) presents with diminished prosthetic clicks, heart failure or embolism and high gradients; confirm with TTE plus TEE, fluoroscopy or CT, then urgent surgery or low-dose slow-infusion fibrinolysis.

The rules

Know these

Mechanical if young; bioprosthetic if over 65A mechanical valve is usually chosen for patients under 50 (aortic) or under 65 (mitral), or already well controlled on warfarin; a bioprosthetic aortic valve is recommended over age 65.

Causes & risk factors

Why it happens

Mechanical valve in pregnancy: warfarin dose decidesMechanical valve in pregnancy: warfarin ≤ 5 mg/day may continue all trimesters; if > 5 mg/day, give dose-adjusted LMWH in the first trimester; switch to heparin ≥ 1 week before delivery; no DOACs.

Management

Orders

Bioprosthetic valve: lifelong low-dose aspirinSurgical bioprosthetic and transcatheter (TAVR) valves get lifelong low-dose aspirin; warfarin for 3–6 months after surgical bioprosthesis is reasonable at low bleeding risk.

Bioprosthetic valve plus AF: DOAC preferredWith a bioprosthetic or transcatheter valve and atrial fibrillation, a DOAC is preferred over warfarin unless thromboembolism has occurred on a DOAC.

Bridge warfarin interruptions — except low-risk mechanical AVRWhen warfarin is interrupted, bridge with unfractionated or low-molecular-weight heparin — except a bileaflet mechanical aortic valve with no thrombosis risk factors (prior thromboembolism, AF, LVEF < 35%, > 1 mechanical valve).

Embolism despite therapeutic INR: add low-dose aspirinIf thromboembolism occurs despite an adequate INR on a mechanical valve, consider adding low-dose aspirin.

Endocarditis prophylaxis before dental proceduresAll patients with prosthetic heart valves get antibiotic endocarditis prophylaxis before dental procedures likely to cause bacteremia; native valve disease alone (eg, mitral stenosis) does not qualify.

Red flags & don'ts

Avoid harm

Bioprosthetic thrombosis: rising gradients, give warfarin complicationBioprosthetic valve thrombosis causes hemodynamic deterioration with rising gradients; TEE or CT distinguishes it from structural degeneration, and a vitamin K antagonist usually relieves the obstruction.

Mechanical or bioprosthetic valve?

Commonly confused

Durability	Lasts; low reintervention
Long-term antithrombotic	Lifelong warfarin
Atrial fibrillation	Warfarin — never a DOAC
Main drawback	Bleeding
Usual patient (aortic)	Under 50, or already on warfarin

More detail

Reference

Show 6 reference facts

From 3 months after an On-X mechanical aortic valve, a lower INR target of 1.5–2.0 with low-dose aspirin may be considered (PROACT).

After TAVR, clopidogrel or warfarin (INR 2.5) may be added to aspirin for 3–6 months in patients at higher thrombosis risk.

Obtain a baseline postoperative TTE; mechanical valves need no routine repeat if stable, bioprostheses need TTE at 5 and 10 years then yearly, and TAVR valves yearly.

INR self-monitoring or a dedicated anticoagulation clinic reduces INR variability and adverse events.

Fibrinolysis for mechanical valve thrombosis succeeds in about 80–90%; low-dose slow or ultra-slow alteplase infusions lower embolic and bleeding complications. Distinguish thrombus from fibrotic pannus ingrowth first.

RE-ALIGN (dabigatran vs warfarin with mechanical valves) was stopped early: ischemic stroke 5% vs 0% and major bleeding 4% vs 2%; apixaban (PROACT Xa, On-X aortic valves) also failed.

Pearl

Mechanical valve, warfarin only: DOACs failed on mechanical valves in RE-ALIGN and PROACT Xa.

Sources · Merck Manual Professional — Overview of Cardiac Valvular Disorders (choice of prosthesis; anticoagulation for prosthetic valves) · Vanassche T et al. Antithrombotic Treatment After Surgical and Transcatheter Heart Valve Repair and Replacement. Front Cardiovasc Med 2021 (compares 2020 ACC/AHA and ESC guidance) · DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives. J Clin Med 2023 (RE-ALIGN, PROACT Xa) · Thrombolysis in Prosthetic Valve Thrombosis: A Safe and Effective Alternative? Cureus 2025 (case and review of guideline positions) · Merck Manual Professional — Mitral Stenosis (endocarditis prophylaxis only after valve replacement) · ACC — 2020 ACC/AHA Heart Valve Disease Guideline: Key Perspectives, Part 3 (antithrombotic therapy for prosthetic valves; pregnancy) · Thrombolytic therapy for mechanical aortic valve thrombosis in pregnancy: case report. Eur Heart J Case Rep 2022 (quotes the 2020 ACC/AHA Class 1 recommendation) · Eikelboom JW et al. Dabigatran versus warfarin in patients with mechanical heart valves (RE-ALIGN). N Engl J Med 2013 · Starter sheet built from the verified AGACNP fact map (facts reviewed 2026-10-15).